Itameline
Alternative Names: RU 47213Latest Information Update: 21 Jan 1997
Price :
$50 *
At a glance
- Originator Aventis
- Class Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Muscarinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 21 Jan 1997 No-Development-Reported for Alzheimer's disease in France (PO)
- 01 Nov 1994 Phase-I clinical trials for Alzheimer's disease in France (PO)